- Home
- BMGL vs ANL Comparison
BMGL vs ANL Comparison
Compare BMGL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMGL
- ANL
- Stock Information
- Founded
- BMGL 2001
- ANL 2004
- Country
- BMGL Singapore
- ANL Cayman Islands
- Employees
- BMGL N/A
- ANL N/A
- Industry
- BMGL
- ANL
- Sector
- BMGL
- ANL
- Exchange
- BMGL NYSE
- ANL Nasdaq
- Market Cap
- BMGL 75.9M
- ANL 79.0M
- IPO Year
- BMGL 2025
- ANL 2023
- Fundamental
- Price
- BMGL $4.45
- ANL $1.71
- Analyst Decision
- BMGL
- ANL Strong Buy
- Analyst Count
- BMGL 0
- ANL 2
- Target Price
- BMGL N/A
- ANL $9.00
- AVG Volume (30 Days)
- BMGL 141.3K
- ANL 5.0K
- Earning Date
- BMGL 01-01-0001
- ANL 04-29-2025
- Dividend Yield
- BMGL N/A
- ANL N/A
- EPS Growth
- BMGL 16.23
- ANL N/A
- EPS
- BMGL 0.09
- ANL N/A
- Revenue
- BMGL $7,428,776.00
- ANL $5,000,000.00
- Revenue This Year
- BMGL N/A
- ANL N/A
- Revenue Next Year
- BMGL N/A
- ANL N/A
- P/E Ratio
- BMGL $47.29
- ANL N/A
- Revenue Growth
- BMGL 3.32
- ANL N/A
- 52 Week Low
- BMGL $3.63
- ANL $1.71
- 52 Week High
- BMGL $5.50
- ANL $15.55
- Technical
- Relative Strength Index (RSI)
- BMGL N/A
- ANL 35.13
- Support Level
- BMGL N/A
- ANL $1.82
- Resistance Level
- BMGL N/A
- ANL $2.16
- Average True Range (ATR)
- BMGL 0.00
- ANL 0.11
- MACD
- BMGL 0.00
- ANL -0.02
- Stochastic Oscillator
- BMGL 0.00
- ANL 3.92
About BMGL BASEL MEDICAL GROUP LTD
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.